Brentuximab Vedotin Plus Bendamustine in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Meta-Analysis

被引：1
|
作者：
Abdelgawad, Hussien Ahmed H. [1 ,2 ]
Belal, Mohamed Mohamed [3 ]
Bashir, Mohamed Nabih [3 ]
Aboeldahab, Heba [4 ,5 ]
Eshun, Francis [1 ,2 ]
Otto, Mario [1 ,2 ]
Henry, Michael [1 ,2 ]
机构：
[1] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA
[2] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ USA
[3] Alexandria Univ, Fac Med, Alexandria, Egypt
[4] El Gomhoria Gen Hosp, Clin Res Dept, Alexandria, Egypt
[5] Alexandria Univ, Med Res Inst, Biomed Informat & Med Stat Dept, Alexandria, Egypt
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187466
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
    Zinzani, Pier Luigi
    Ramchandren, Radhakrishnan
    Santoro, Armando
    Paszkiewicz-Kozik, Ewa
    Gasiorowski, Robin
    Johnson, Nathalie A.
    de Oliveira, Jose S. R.
    Buccheri, Valeria
    Perini, Guilherme Fleury
    Dickinson, Michael
    McDonald, Andrew
    Ozcan, Muhit
    Sekiguchi, Naohiro
    Zhu, Ying
    Raut, Monika
    Saretsky, Todd L.
    Nahar, Akash
    Kuruvilla, John
    BLOOD ADVANCES, 2022, 6 (02) : 590 - 599
  • [32] Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era
    Graf, Solomon A.
    Gopal, Ajay K.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 151 - 157
  • [33] Nivolumab plus Brentuximab vedotin plus /- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
    Greve, Patrick
    Beishuizen, Auke
    Hagleitner, Melanie
    Loeffen, Jan
    Veening, Margreet
    Boes, Marianne
    Peperzak, Victor
    Diez, Claudius
    Meyer-Wentrup, Friederike
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
    A. Salihoglu
    T. Elverdi
    I. Karadogan
    S. Paydas
    E. Ozdemir
    G. Erdem
    N. Karadurmus
    G. Akyol
    L. Kaynar
    ZA Yegin
    G. Sucak
    V. Ozkocaman
    P. Topcuoglu
    M. Ozcan
    E. Birtas
    H. Goker
    Z. Baslar
    B. Ferhanoglu
    Annals of Hematology, 2015, 94 : 415 - 420
  • [35] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
    Ferhanoglu, B.
    Salihoglu, A.
    Elverdi, T.
    Karadogan, I.
    Ozdemir, E.
    Erdem, G.
    Karadurmus, N.
    Akyol, G.
    Kaynar, L.
    Yegin, A.
    Sucak, G.
    Ozkocaman, V.
    Topcuoglu, P.
    Ozcan, M.
    Birtas, E.
    Goker, H.
    Baslar, Z.
    Paydas, S.
    HAEMATOLOGICA, 2014, 99 : 675 - 676
  • [36] Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
    Wang, Z.
    Sun, K.
    Zhu, Z-M
    Zhang, P.
    Yang, J.
    Yang, S-W
    Zheng, M-Q
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (07) : 2941 - 2948
  • [37] Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
    Tien, Feng-Ming
    Tsai, Cheng-Hong
    Liu, Jia-Hau
    Lin, Chien-Ting
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (10) : 1466 - 1470
  • [38] THE VALUE OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS BASED ON POOLED-ANALYSIS
    Dada, R.
    Zekri, J.
    Bayoumy, M.
    Al Saadi, R.
    HAEMATOLOGICA, 2016, 101 : 54 - 55
  • [39] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    Pinczes, Laszlo Imre
    Szabo, Roxana
    Illes, Arpad
    Foldeak, Dora
    Piukovics, Klara
    Szomor, Arpad
    Gopcsa, Laszlo
    Miltenyi, Zsofia
    ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2385 - 2392
  • [40] Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
    László Imre Pinczés
    Roxána Szabó
    Árpád Illés
    Dóra Földeák
    Klára Piukovics
    Árpád Szomor
    László Gopcsa
    Zsófia Miltényi
    Annals of Hematology, 2020, 99 : 2385 - 2392
12345